Researchers Explore How the Human Body Uses Copper to Fight Bacterial Infections

Key facts

According to reporting by phys.org, investigators at Texas A&M University's VMBS have centered their attention on the biochemical interaction between host defenses and bacterial pathogens in the urinary tract. When pathogens enter the urinary system, the host organism initiates a multi-layered immune cascade. Part of this physiological response involves altering the local concentration of trace elements, specifically turning copper from a required nutrient into a localized antimicrobial agent.

The Texas A&M team is examining how host cells concentrate copper ions within specialized compartments or secrete them into infected tissues to target invading microbes. Bacteria require miniscule amounts of copper for enzymatic functions, but elevated concentrations generate reactive oxygen species, destroy iron-sulfur clusters in bacterial enzymes, and dismantle vital cell membrane structures. By mapping the pathways that regulate copper transport during urinary tract infections, the researchers seek to understand how host tissues calibrate metal levels to kill bacteria without causing systemic toxicity to the host.

Why it matters

The investigation into copper-mediated immunity addresses one of modern medicine's most severe structural crises: the global expansion of antimicrobial resistance. The World Health Organization has declared drug-resistant infections a top global public health threat. A landmark analysis published in The Lancet estimated that bacterial antimicrobial resistance was directly responsible for 1.27 million deaths globally in 2019 and associated with nearly 5 million total deaths annually.

Urinary tract infections (UTIs) are among the most prevalent outpatient and hospital-acquired bacterial conditions, affecting an estimated 150 million people worldwide each year. Traditionally treated with standard oral antibiotics such as trimethoprim-sulfamethoxazole, nitrofurantoin, or fluoroquinolones, UTIs are increasingly caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and other multidrug-resistant pathogens. When first-line therapies fail, patients face prolonged illness, higher healthcare costs, increased risk of kidney damage, and dangerous systemic escalation such as urosepsis.

If biomedical scientists can elucidate how host cells naturally use copper to neutralize pathogens, pharmaceutical developers could design adjunctive therapies that amplify this intrinsic defense. Rather than developing traditional synthetic antibiotics—to which bacteria rapidly adapt through gene mutation or plasmid transfer—therapeutics could potentially bolster host copper-transporter activity or deliver copper-mimicking compounds directly to infection sites, bypassing conventional resistance mechanisms.

The antimicrobial properties of metallic copper have been recognized empirically for millennia. Ancient Egyptian medical texts, including the Smith Papyrus compiled around 1500 BCE, recorded the use of copper compounds to sterilize drinking water and treat chest wounds. In modern infection control, solid copper alloys are widely utilized on hospital touch surfaces due to "contact killing," a physical phenomenon where microbial membranes rupture and cellular DNA degrades within minutes of contacting copper ions.

Within cellular biology, however, the understanding of copper has shifted dramatically over the past two decades. Historically, immunology research centered heavily on iron sequestration—a process where the host hides iron from bacteria to starve them of a critical growth factor. More recent biochemical studies have demonstrated that host immune cells, particularly macrophages and epithelial linings, also employ metal toxicity as an offensive tactic.

During an infection, specialized host transport proteins, such as P-type ATPase ATP7A, relocate within host cells to pump copper ions directly into phagosomes—the intracellular chambers where immune cells engulf bacteria. In response, bacteria have evolved sophisticated efflux pumps, such as CopA and CueO systems, designed to pump excess copper out of their cytoplasm. This evolutionary arms race between host copper delivery and microbial copper expulsion determines whether an infection takes hold or is successfully cleared. The research at Texas A&M VMBS builds upon this foundation by analyzing these metal-handling pathways specifically within the context of the urinary tract's unique physiological environment.

Reaction

While specific formal statements from outside regulatory bodies have not been released alongside the preliminary research findings, the broader infectious disease and veterinary medicine communities have expressed strong interest in alternative, non-antibiotic strategies. Microbiologists and clinical pharmacologists routinely highlight that understanding host-directed pathways is essential as the pipeline for new conventional antibiotic classes remains severely constrained.

Academic institutions operating within the "One Health" framework—which integrates human, animal, and environmental health research—frequently emphasize that urinary tract infections affect both human patients and domestic animals, particularly dogs and cats. Veterinary researchers expect that findings from Texas A&M will provide dual benefits, offering veterinary clinicians new approaches to manage resistant animal UTIs while simultaneously contributing comparative data relevant to human medicine.

What we don't know yet

Several critical questions remain open as the Texas A&M research progresses. First, the precise threshold at which copper levels become lethal to pathogenic bacteria while remaining entirely safe for human urothelial cells has not been fully quantified across different tissue microenvironments. Copper is a highly reactive transition metal, and excess localized accumulation carries the risk of tissue damage, inflammation, or cytotoxicity in host organs.

Second, it remains unverified to what extent clinical strains of uropathogenic bacteria isolated from human patients possess advanced copper-resistance mutations. If widespread antibiotic usage has indirectly selected for bacteria with hyper-active metal efflux systems, host-directed copper strategies might face biological resistance mechanisms that are not yet characterized. Finally, the published reporting does not specify whether the research has moved beyond in vitro cellular models and animal models into early-stage human clinical evaluations, leaving the timeline for translational clinical application uncertain.

What to watch

In the coming months and years, several key milestones will clarify the trajectory of host-targeted copper research:

This report is based on original reporting published by phys.org.